Dr. Jason Bock has a history of building organizations to develop biologic therapeutics to impact patients. In 2019, Dr. Bock was recruited by The University of Texas MD Anderson Cancer Center to build the Biologics Development group, which serves as an internal biotech to support development of MDACC-invented biologics. In May 2022, the group spun out into a joint venture between MD Anderson Cancer Center + Resilience to form CTMC, with Dr. Bock as CEO.
CTMC was created to bring together innovative academic science with industrial drug development and advanced manufacturing capabilities to rapidly enable cell therapies that impact patients. The company is headquartered in a 60,000 SF cell therapy manufacturing facility in the Texas Medical Center with 14 cleanrooms, process and analytical labs, and office space just steps from MD Anderson’s main building. Since its inception, CTMC has successfully navigated 3 novel cell therapies through IND clearance and is on track to submit 6 novel cell therapies for IND clearance in the coming 18 months.
Previously Dr. Bock was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. During his 10 years at Teva, he grew the Biologics team to over 600 employees, brought 15 novel drugs through preclinical development into clinical studies, and drove three biologics through the clinic into commercialization globally. He joined Teva through the acquisition of CoGenesys, a private biotech firm that was a spinoff from Human Genome Sciences (HGS), where he began his career.
Dr. Bock received a B.S. in Biology from MIT and a Ph.D. in Molecular and Cellular Physiology from Stanford University.Sessions: